ProCE Banner Activity

KEYNOTE-522 Study of Neoadjuvant Pembrolizumab vs Placebo in Combination With Chemotherapy for Early-Stage TNBC: Subgroup Analysis of pCR

Slideset Download
Conference Coverage
Neoadjuvant pembrolizumab plus chemotherapy associated with pCR benefit vs chemotherapy alone in patients with early-stage TNBC across multiple subgroups.

Released: December 19, 2019

Expiration: December 17, 2020

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen